Arista Cognitive Cloud Networking Redefines the Campus
Reading Time: 5 minutes
New Cognitive Edge with PoE Leaf and WiFi endorsed by partners
SANTA CLARA, Calif.–(BUSINESS WIRE)–Arista Networks (NYSE:ANET) today announced an expansion of the cognitive
campus portfolio with unified wired and wireless campus edge
products designed to address transitional changes as the enterprise
moves to an IoT (Internet of Things)-ready campus. Extending EOS®
and CloudVision®,
Arista’s Cognitive Cloud Networking approach brings operational
consistency and modern cloud principles to the enterprise campus.
This approach, combined with key
partnerships, helps reduce customer operational expenses through
simplified architectures, data-driven analytics and segment-based
security. With these wired and wireless edge additions, Arista now has a
complete cognitive enterprise networking portfolio, spanning the
datacenter, the cloud and the campus.
“Arista’s software-first approach simplifies network designs across all
of our switches from the datacenter to the campus. The benefit of a
single EOS and common CloudVision management plane is operational
consistency, which means time savings for our network operations team,”
Jonathan Skelley, Director of IS Infrastructure, Roper St. Francis
Healthcare.
Arista’s Cognitive Campus for Simplicity and Cloud Principles:
Today’s campus networks continue to suffer from too much complexity
brought on by the myriad platforms, operating systems, proprietary
features and network management tools from incumbent vendors. Coupled
with the explosive growth of endpoints these challenges are not unlike
those of legacy datacenters, before the shift to cloud networking. The
cloud networking principles of simplification, open-standards,
software-driven control are just as applicable to today’s campus
networks.
“Our experience with Arista in our datacenter deployments has been so
successful, that we are thrilled that we can now extend Arista’s campus
switching products to our broader enterprise networks,” Ariel Pisetzky,
Vice President, IT, Taboola.
The Arista Cognitive Campus is a software-driven approach to unify wired
and wireless campus access built on real-time, data-driven analytics
that focus on delivering a great user and operator experience. The
Arista Cognitive Campus leverages the Arista Universal Cloud Network
(UCN) architecture developed for the world’s largest datacenters. In
2018, Arista introduced the 7300X3
and 7050X3
as the Campus Spline
and later the controller-less Cognitive WiFi
product family. Arista CloudVision and the Cognitive Management Plane
were also extended to include campus specific use-cases for wired and
wireless.
Introducing the Cognitive Campus Edge
The Arista 720XP
Series represents Arista’s first purpose-built campus leaf products
and are a key addition bringing the wired edge component to Arista’s
Cognitive Campus portfolio. With the 720XP, customers will benefit from
improved security and visibility as they are able to gain a more
holistic understanding of endpoint behaviors across users, mobile
devices, and IoT platforms.
The 720XP Series includes four fixed configuration models and offers
capabilities for new multi-gigabit access port speeds (2.5GBASE-T and
5GBASE-T) enabling the transition to higher speed access devices, up to
60 watts of Power over Ethernet (PoE) for powering IP phones, access
points, and IoT devices, and a choice of 25G, 40G and 100G uplink ports
for connectivity to Arista Campus Spline platforms.
As with all Arista switching products, the 720XP Series leverage the
same Arista EOS and CloudVision software, bringing a consistent and
simplified operational model to the campus edge. With that, these
products provide the following new benefits to campus network operators:
-
Device Analyzer, providing endpoint inventory and deep flow analysis
for all connected devices and helping to proactively identify security
threat vectors. -
Cloud-like operations, including workflows to simplify change controls
though network-wide automation, to reduce the maintenance windows
duration, and to quickly assess network compliance. -
Network access control integration through standard RADIUS solutions
as well as a standards-based group-based segmentation approach with
VXLAN and EVPN. -
Wireless mobility and roaming, leveraging integrated VXLAN tunnel
termination instead of legacy controller-based options. -
Expanded device support to manage PoE usage through CloudVision’s
dashboards. -
End-to-end Troubleshooting – leverage CloudVision’s network-wide
database for unprecedented time-series visibility across campus,
datacenter, and cloud networks in a single view.
The 720XP Series is designed to address the next generation campus edge
requirements, with cognitive capabilities for real-time flow analytics
compared to traditional campus monitoring approaches.
Unified Cognitive WiFi
These new campus leaf switches integrate directly with Arista’s
Cognitive WiFi portfolio, including Arista’s first WiFi 6 access point.
The new C-250 access point supports the full 802.11ax standard including
8×8 MU-MIMO, uplink OFDMA & MU-MIMO. Like other Arista enterprise access
points, it also includes a 2×2 dual band 3rd radio. With target use
cases for WiFi 6 such as higher bandwidth video, and many more
simultaneous users, the 3rd radio will be essential. Along with a
variety of other data sources, the 3rd radio provides a continuous
stream of telemetry data into Arista’s Cognitive WiFi architecture where
the power of cloud is harnessed to apply machine learning and cognitive
intelligence.
CloudVision WiFi delivers real-time insight into the WiFi client
journey, including the health of the network services, the user’s
ability to connect, and delivering great WiFi experiences through
analytics and proactive remediation. With CloudVision WiFi, Arista is
delivering a modern and technologically advanced controller-less WiFi
solution to customers.
Expanded Campus Ecosystem
Arista’s enterprise focus also includes a broader partnership scope,
including an ecosystem of channel partners, managed services partners,
and technology partners.
Arista’s channel partner program focuses on enterprise go to market and
includes tiered partner levels, each of which has appropriate goals,
training, and resourcing. Arista is partnering with managed service
providers for the rollout and operations of Arista network technologies,
as enterprise customers consider outsourced operational models. The
initial managed services partners include Comcast, NTT and Tech Mahindra.
By leveraging the Microsoft
Azure cloud platform and through technology partnerships with
companies, including Forescout, Arista is extending its existing
best-of-breed technology partner ecosystem. Arista’s technology
partnerships are addressing campus to cloud visibility as well as
improved device posture and compliance through certification with the
Forescout platform of the new 720XP Series switches. See supporting
quotes here.
Availability
The 720XP Series platforms, the C-250 WiFi 6 access point, and the
associated cognitive EOS and CloudVision capabilities are in trials now
with general availability in Q3’19.
Register here
to learn more about Arista’s Cognitive Campus at our webinar on June 20,
2019.
About Arista Networks
Arista Networks pioneered software-driven, cognitive cloud networking
for large-scale datacenter and campus environments. Arista’s
award-winning platforms redefine and deliver availability, agility,
automation, analytics, and security. Arista has shipped more than twenty
million cloud networking ports worldwide with CloudVision and EOS, an
advanced network operating system. Committed to open standards across
private, public and hybrid cloud solutions, Arista products are
supported worldwide directly and through partners.
ARISTA, EOS, CloudVision, Flexroute and AlgoMatch are among the
registered and unregistered trademarks of Arista Networks, Inc. in
jurisdictions around the world. Other company names or product names may
be trademarks of their respective owners. Additional information and
resources can be found at www.arista.com.
This press release contains forward-looking statements including, but
not limited to, statements regarding performance, cost savings, user
experience, and security. All statements other than statements of
historical fact are statements that could be deemed forward-looking
statements. Forward-looking statements are subject to risks and
uncertainties that could cause actual performance or results to differ
materially from those expressed in the forward-looking statements
including: our limited operating history and experience with developing
and releasing new products; product, support or service quality
problems; rapidly evolving changes in technology, customer requirements
and industry standards as well as other risks stated in our filings with
the SEC available on Arista’s website at www.arista.com
and the SEC’s website at www.sec.gov.
Arista disclaims any obligation to publicly update or revise any
forward-looking statement to reflect events that occur or circumstances
that exist after the date on which they were made.
Contacts
Media Contact
Amanda Jaramillo
Corporate Communications
Tel:
(408) 547-5798
[email protected]
Investor Contact
Charles Yager
Product and Investor Advocacy
Tel:
(408) 547-5892
[email protected]
TORONTO and GLIL YAM, Israel, Sept. 11, 2024 /PRNewswire/ — IM Cannabis Corp. (“IMC” or the “Company“) (NASDAQ: IMCC) (CSE: IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that Mr. Shmulik Arbel has been appointed to the Company’s board of directors (the “Board“) effective September 9, 2024. Mr. Arbel brings a wealth of experience in strategic plans that drive profitability, as well as, finance and corporate governance, further strengthening the company’s commitment to driving growth while focusing on sustainable profitability.
“We are thrilled to welcome Shmulik to our Board of Directors,” said Oren Shuster, Chief Executive Officer of IM Cannabis. “Shmulik’s extensive international experience at Leumi, coupled with his proven track record in banking and finance will be invaluable as we continue to deliver on our strategic initiatives.”
Mr. Arbel retired as Deputy CEO from Leumi, Israel’s largest banking group, in April 2023, where he was instrumental in business growth and leading the service revolution. With over 25 years of experience at Leumi, Arbel has held senior roles throughout the organization, such as head of retail banking, head of the corporate division, and as chairman of Leumi UK. With key roles in Israel, New York and London, Mr. Arbel has a wide view on international business.
“I am honored to join the Board of Directors at IMCC,” said Mr. Arbel. “I look forward to leveraging my experience in banking and finance, providing guidance as IMCC continues to establish itself as the go-to brand in the cannabis world. I look forward to contributing to the company’s growth.”
Arbel holds a BA and MBA from Tel Aviv University.
About IM Cannabis Corp.
IMC (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company has focused its resources to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.
The IMC ecosystem operates in Israel through its commercial relationship with Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients.
Disclaimer for Forward-Looking Statements
This press release contains forward-looking information or forward-looking statements under applicable Canadian and United States securities laws (collectively, “forward-looking statements“). All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “likely” and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements relating to: the stated benefits Mr. Arbel’s appointment, including the further strengthening the Company’s commitment to driving growth in the German market while focusing on sustainable profitability; and Mr. Arbel’s international experience and track record in banking and finance will be invaluable to the Company.
Forward-looking statements are based on assumptions that may prove to be incorrect, including but not limited to: the Company’s ability to realize upon the stated benefits Mr. Arbel’s appointment; and Mr. Arbel’s international experience and track record in banking and finance becoming invaluable to the Company.
The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward-looking statements due to a number of factors and risks. These include: the failure of the Company to comply with applicable regulatory requirements in a highly regulated industry; unexpected changes in governmental policies and regulations in the jurisdictions in which the Company operates; the Company’s ability to continue to meet the listing requirements of the Canadian Securities Exchange and the NASDAQ Capital Market; any unexpected failure to maintain in good standing or renew its licenses; the ability of the Company and its subsidiaries (collectively, the “Group“) to deliver on their sales commitments or growth objectives; the reliance of the Group on third-party supply agreements to provide sufficient quantities of medical cannabis to fulfil the Group’s obligations; the Group’s possible exposure to liability, the perceived level of risk related thereto, and the anticipated results of any litigation or other similar disputes or legal proceedings involving the Group; the impact of increasing competition; any lack of merger and acquisition opportunities; adverse market conditions; the inherent uncertainty of production quantities, qualities and cost estimates and the potential for unexpected costs and expenses; risks of product liability and other safety-related liability from the usage of the Group’s cannabis products; supply chain constraints; reliance on key personnel; the risk of defaulting on existing debt; risks surrounding war, conflict and civil unrest in Eastern Europe and the Middle East, including the impact of the Israel-Hamas war on the Company, its operations and the medical cannabis industry in Israel; risks associated with the Company focusing on the Israel and Germany markets; the inability of the Company to achieve sustainable profitability and/or increase shareholder value; the inability of the Company to actively manage costs and/or improve margins; the inability of the company to grow and/or maintain sales; the inability of the Company to meet its goals and/or strategic plans; the inability of the Company to reduce costs and/or maintain revenues; the Company’s inability to take advantage of the legalization of medicinal cannabis in Germany; and the Company’s inability to realize upon the stated benefits Mr. Arbel’s appointment; and Mr. Arbel’s international experience and track record in banking and finance not becoming valuable to the Company.
Please see the other risks, uncertainties and factors set out under the heading “Risk Factors” in the Company’s annual report dated March 28, 2024, which is available on the Company’s issuer profile on SEDAR+ at www.sedarplus.ca and Edgar at www.sec.gov/edgar. Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward looking information is made. The Company does not undertake any obligation to update forward-looking statements except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.
Company Contact:
Anna Taranko, Director Investor & Public Relations
IM Cannabis Corp.
+49 157 80554338
[email protected]
Oren Shuster, CEO
IM Cannabis Corp.
[email protected]
Logo: https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/im-cannabis-announces-appointment-of-shmulik-arbel-to-board-of-directors-302244961.html
Indivior
Indivior Provides Update on Aelis Farma’s Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018).
- Primary and Secondary End Points of the Study were Not Met
- Indivior Does Not Currently Expect to Exercise AEF0117 Option
SLOUGH, United Kingdom and RICHMOND, Va., Sept. 4, 2024 /PRNewswire/ — Indivior PLC (Nasdaq/LSE: INDV) is today providing an update following Aelis Farma’s announcement of the results from its clinical Phase 2B trial with AEF01171, evaluating the efficacy and safety in treatment-seeking participants with moderate to severe Cannabis Use Disorder (CUD). The purpose of this trial was twofold: (1) to show that AEF0117 (0.1, 0.3, 1 mg once a day for 12 weeks) lowers cannabis use and (2) to determine the endpoints and optimal dosage of AEF0117 for use in future studies. In this phase 2B study, patients were treatment-seeking participants, 84% of whom had severe CUD.
The results of the study demonstrated that the primary endpoint, the proportion of participants who reduced their cannabis use to ≤1 day per week, as well as secondary endpoints measuring the proportion of participants reaching either complete abstinence or who used ≤2 day per week, were not met. Although these results are disappointing, they indicate that significant work remains to be done to understand subpopulations of patients with CUD, specifically those with severe CUD.
This clinical Phase 2B study is part of the strategic collaboration between Aelis Farma and Indivior, which includes an exclusive option for Indivior to license the global rights to AEF0117. Given the lack of separation from placebo on primary and secondary endpoints and before seeing further additional favorable clinical data, Indivior does not currently expect to exercise its option.
Important Cautionary Note Regarding Forward-Looking Statements
This news release contains certain statements that are forward-looking. Forward-looking statements include, among other things, express and implied statements regarding whether: we will be able to ultimately demonstrate the safety and efficacy of AEF0117, which is a prerequisite to filing any New Drug Application; we might ever exercise our option for AEF0117 and, if so, when; and other statements containing the words “believe,” “anticipate,” “plan,” “expect,” “intend,” “estimate,” “forecast,” “strategy,” “target,” “guidance,” “outlook,” “potential,” “project,” “priority,” “may,” “will,” “should,” “would,” “could,” “can,” “outlook,” “guidance,” the negatives thereof, and variations thereon and similar expressions. By their nature, forward-looking statements involve risks and uncertainties as they relate to events or circumstances that may or may not occur in the future.
Actual results may differ materially from those because they relate to future events. Various factors may cause differences between Indivior’s expectations and actual results, including, among others, the risks described in our most recent annual report on Form 20-F beginning on page 9 as filed with the U.S. SEC and in subsequent releases; legal and market restrictions that may limit how quickly we can repurchaser our shares; the substantial litigation and ongoing investigations to which we are or may become a party; our reliance on third parties to manufacture commercial supplies of most of our products, conduct our clinical trials and at times to collaborate on products in our pipeline; our ability to comply with legal and regulatory settlements, healthcare laws and regulations, requirements imposed by regulatory agencies and payment and reporting obligations under government pricing programs; risks related to the manufacture and distribution of our products, most of which contain controlled substances; market acceptance of our products as well as our ability to commercialize our products and compete with other market participants; competition; the uncertainties related to the development of new products, including through acquisitions, and the related regulatory approval process; our dependence on third-party payors for the reimbursement of our products and the increasing focus on pricing and competition in our industry; unintended side effects caused by the clinical study or commercial use of our products; our ability to successfully execute acquisitions, partnerships, joint ventures, dispositions or other strategic acquisitions; our ability to protect our intellectual property rights and the substantial cost of litigation or other proceedings related to intellectual property rights; the risks related to product liability claims or product recalls; the significant amount of laws and regulations that we are subject to, including due to the international nature of our business; macroeconomic trends and other global developments such as armed conflicts and pandemics; the terms of our debt instruments, changes in our credit ratings and our ability to service our indebtedness and other obligations as they come due; changes in applicable tax rate or tax rules, regulations or interpretations and our ability to realize our deferred tax assets; and volatility in our share price due to factors unrelated to our operating performance or that may result from the potential move of our primary listing to the U.S.
Forward-looking statements speak only as of the date that they are made and should be regarded solely as our current plans, estimates and beliefs. Except as required by law, we do not undertake and specifically decline any obligation to update, republish or revise forward-looking statements to reflect future events or circumstances or to reflect the occurrences of unanticipated events.
This release is being made by Kathryn Hudson, Company Secretary Indivior PLC.
About Indivior
Indivior is a global pharmaceutical company working to help change patients’ lives by developing medicines to treat substance use disorders (SUD), overdose and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease.
Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD. Headquartered in the United States in Richmond, VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.
References:
- National Library of Medicine (U.S.) (2022, April). Effect of AEF0117 on treatment-seeking patients with cannabis use disorder (CUD) (SICA2). Identifier
NCT05322941 https://www.clinicaltrials.gov/study/NCT05322941
Logo – https://mma.prnewswire.com/media/1814851/Indivior_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/indivior-provides-update-on-aelis-farmas-clinical-phase-2b-study-results-with-aef0117-in-participants-with-cannabis-use-disorder-302237355.html
